150 likes | 382 Views
Air Toxics Exposure: Relevance to Risk Assessment. TCEQ/NUATRC Air Toxics Workshop October 17, 2005 Tina Bahadori, D. Sc. Long-Range Research Initiative American Chemistry Council. GPRA Goals (source: EPA Air Toxics Research Strategy draft 2002).
E N D
Air Toxics Exposure:Relevance to Risk Assessment TCEQ/NUATRC Air Toxics Workshop October 17, 2005 Tina Bahadori, D. Sc. Long-Range Research Initiative American Chemistry Council
GPRA Goals (source: EPA Air Toxics Research Strategy draft 2002) • “By 2010, reduce air toxics emissions by 75% from 1993 levels.” • “By 2020, eliminate unacceptable risks of cancer and other significant health problems from air toxics emissions for at least 95% of the population, with particular attention to children and other sensitive subpopulations…”
Foundation for Decision-Making MACT Std’s Residual Risk Std’s Urban Area Source Std’s Community Initiatives Utility Determination & Actions Mobile Source Std’s Combustion Std’s NATA HEALTH RISK INFORMATION Is it sufficient?
“Individual” Air Toxics 188 CAA 34 NATA 21 Mobile Source 18 Indoor Air The Conundrum Facility SOURCE 1 SOURCE 2 SOURCE 3 8-9 Yr after MACT: Residual Risk? Ample margin of safety test.
RfC Lifetime continuous exposure Adverse effects unlikely in sensitive groups NOAEL/BMD (human adj)/UF’s: NOAEL, interspecies, intraspecies, chronic, database Linear Multi-Stage Model Lifetime continuous exposure Upper bound excess lifetime cancer risk Risk unlikely to exceed upper bound Risk likely to be somewhere between 0 and upper bound
Current and Future Needs • Improve risk assessment methodologies • consideration of real-world exposures (e.g., dose-rate, intermittent) • reduced reliance on generic defaults, • harmonization of cancer and noncancer methods • Expand research on complex mixtures of air toxics • Use available health information in state-of-the-science assessments, in time for regulatory use • Prioritize and fill chemical-specific health data gaps in context of the risk “wheel”
The ACC’s Long-Range Research Initiative (LRI) • Goal: Provide fundamental research essential to improving chemical testing and risk assessment practices and policies • Research independence • PIs select chemicals • PIs “own” data and publish in peer-reviewed literature without ACC approval • Research conducted according to • MOU with CIIT Centers for Health Research • Competitive RfP program, often with other federal agencies
LRI Air Toxics Program • Human Exposure Studies • Atmospheric formation of air toxics mixtures, with identification of toxic components (UNC) • Measurement of indoor, outdoor, and personal exposures to VOCs in several areas of Boston and Detroit (Harvard,U.MI) • Improve air toxics exposure models (EOHSI with EPA/NERL & OAQPS)
LRI Air Toxics Program • Dose Studies • Respiratory tract dosimetry modeling, reactive gases and particles (CIIT) • Animal-to-human extrapolation • Human age models • Age-dependent pharmacokinetic modeling for systemically acting chemicals (CIIT, ENVIRON) • Chlorine dosimetry (CIIT)
LRI Air Toxics Program • Health Effects and Assessment Studies • Chlorine dose-response modeling (CIIT) • Mechanisms of acute lung injury (CIIT) • Lung biomarkers (CIIT) • Methods for developmental effects (EPA, Cornell, TNO, CIIT) • Chloroform computational modeling (CIIT) • Functional genomics (CIIT) • BB-DR modeling (CIIT, Colorado State, Gradient)
For more information on LRI www.uslri.org Tina_Bahadori@americanchemistry.com
Far More Advanced Assessment Methods Available, if Database Rich • Noncancer • Expert judgment (e.g., EPA ozone) • Advanced BMD and Bayesian analyses (e.g., EPA Mn) • Probabilistic UF’s (e.g., pubs, mostly for RfD’s) • 1999/2003 EPA’s Draft Revised Cancer Guidelines • Mode of action • Biologically-based dose-response modeling • Margin of exposure • 2003 supplement for early-life exposure
Research Causes Evolution of Formaldehyde Cancer Assessment • Early 80’s, nasal cancers in rodents, >6ppm • Later • rat-human nasal dose models • mode of action (DPX & CRCP) • 2-stage clonal growth model link of DPX & CRCP with tumors